Labcorp (NYSE: LH) EVP granted performance stock; shares withheld for tax

Q: What insider transactions did LH executive Mark Schroeder report?

Mark S. Schroeder reported equity compensation activity in Labcorp common stock. He received performance-based share awards and had shares withheld to satisfy tax obligations , with no open-market buying or selling disclosed in these transactions.

Q: How many Labcorp (LH) shares did Mark Schroeder acquire?

Mark Schroeder acquired 9,304 shares from a February 7, 2023 performance award and 2,968 shares from a May 5, 2023 performance award, both linked to three-year performance ending December 31, 2025.

Q: How many Labcorp (LH) shares were withheld for taxes in this Form 4?

A total of 4,600 shares and 1,468 shares of Labcorp common stock were withheld to satisfy tax withholding obligations , with the withholding transactions recorded at $268.38 per share .

Q: Were Mark Schroeder’s Labcorp (LH) awards tied to company performance?

Yes. The shares were acquired pursuant to performance awards granted on February 7, 2023 and May 5, 2023 , each relating to Labcorp’s performance over the three-year period ended December 31, 2025.

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

LABCORP HOLDINGS INC. executive Mark S. Schroeder, EVP and President of Diagnostics & COO, reported equity compensation activity in the company’s common stock. On March 26, 2026, he acquired 9,304 shares pursuant to a performance award granted on February 7, 2023 and 2,968 shares pursuant to a performance award granted on May 5, 2023, both tied to performance for the three-year period ended December 31, 2025. To cover tax withholding obligations, 4,600 shares and 1,468 shares were withheld at a price of $268.38 per share. Following these grant and tax-withholding transactions, he directly held 12,677.1426 shares of common stock.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Schroeder Mark S

Role EVP, Pres Diagnostics & COO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	9,304	$0.00	--
Tax Withholding	Common Stock	4,600	$268.38	$1.23M
Grant/Award	Common Stock	2,968	$0.00	--
Tax Withholding	Common Stock	1,468	$268.38	$394K

Holdings After Transaction: Common Stock — 15,777.143 shares (Direct)

Footnotes (1)

Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Stock withholding to satisfy tax withholding obligations. Shares acquired on March 26, 2026, pursuant to a performance award granted on May 5, 2023, relating to performance during the three-year period ended December 31, 2025.

Key Figures

Performance award shares (Feb 2023 grant): 9,304 shares Performance award shares (May 2023 grant): 2,968 shares Tax withholding block 1: 4,600 shares at $268.38 +3 more

6 metrics

Performance award shares (Feb 2023 grant) 9,304 shares Common stock acquired March 26, 2026 from February 7, 2023 performance award

Performance award shares (May 2023 grant) 2,968 shares Common stock acquired March 26, 2026 from May 5, 2023 performance award

Tax withholding block 1 4,600 shares at $268.38 Shares withheld to satisfy tax withholding obligations

Tax withholding block 2 1,468 shares at $268.38 Additional shares withheld to satisfy tax withholding obligations

Total tax withholding shares 6,068 shares Aggregate shares withheld for tax obligations in Form 4

Shares held after transactions 12,677.1426 shares Direct Labcorp common stock holdings following March 26, 2026 activity

Key Terms

performance award, three-year period, Stock withholding, tax withholding obligations

4 terms

performance award financial

"Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023"

three-year period financial

"relating to performance during the three-year period ended December 31, 2025"

Stock withholding financial

"Stock withholding to satisfy tax withholding obligations."

tax withholding obligations financial

"Stock withholding to satisfy tax withholding obligations."

Form 4 Insider Transactions: What Each Field Means →

03/30/2026 - 12:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schroeder Mark S

(Last)

(First)

(Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON

NORTH CAROLINA

27215

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Pres Diagnostics & COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/26/2026		A⁽¹⁾		9,304	A	$0	15,777.1426	D
Common Stock	03/26/2026		F⁽²⁾		4,600	D	$268.38	11,177.1426	D
Common Stock	03/26/2026		A⁽³⁾		2,968	A	$0	14,145.1426	D
Common Stock	03/26/2026		F⁽²⁾		1,468	D	$268.38	12,677.1426	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.

2. Stock withholding to satisfy tax withholding obligations.

3. Shares acquired on March 26, 2026, pursuant to a performance award granted on May 5, 2023, relating to performance during the three-year period ended December 31, 2025.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Mark S. Schroeder	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did LH executive Mark Schroeder report?

Mark S. Schroeder reported equity compensation activity in Labcorp common stock. He received performance-based share awards and had shares withheld to satisfy tax obligations, with no open-market buying or selling disclosed in these transactions.

How many Labcorp (LH) shares did Mark Schroeder acquire?

Mark Schroeder acquired 9,304 shares from a February 7, 2023 performance award and 2,968 shares from a May 5, 2023 performance award, both linked to three-year performance ending December 31, 2025.

How many Labcorp (LH) shares were withheld for taxes in this Form 4?

A total of 4,600 shares and 1,468 shares of Labcorp common stock were withheld to satisfy tax withholding obligations, with the withholding transactions recorded at $268.38 per share.

What is Mark Schroeder’s Labcorp (LH) shareholding after these transactions?

After the reported grant and tax-withholding transactions, Mark S. Schroeder directly held 12,677.1426 shares of Labcorp common stock, as reflected in the post-transaction holdings field of the Form 4.

Were Mark Schroeder’s Labcorp (LH) awards tied to company performance?

Yes. The shares were acquired pursuant to performance awards granted on February 7, 2023 and May 5, 2023, each relating to Labcorp’s performance over the three-year period ended December 31, 2025.